Company news
Alvotech news in 2023
Alvotech's news releases, calls and decks from 2023, newest first.
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
November 28, 2023
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
November 27, 2023
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8: 00 am ET
November 20, 2023
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)
November 13, 2023
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
October 11, 2023
Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland
October 4, 2023
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
October 2, 2023
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
September 24, 2023
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
September 19, 2023
Alvotech Announces Changes to the Leadership Team
September 4, 2023
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
August 29, 2023
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
August 28, 2023
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8: 00 am ET
August 21, 2023
Alvotech Completes $100 Million Convertible Bond Private Placement
July 30, 2023
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
June 27, 2023
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
June 11, 2023
Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
May 23, 2023
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
May 18, 2023
Alvotech Issues Annual Equality Report Covering 2022
May 14, 2023
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
May 9, 2023
Alvotech S.A. Annual General Meeting to be held June 6, 2023
May 4, 2023
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
May 3, 2023
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8: 00 am ET
May 2, 2023
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer
April 18, 2023
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
April 12, 2023
Alvotech Provides Update on Corporate Sustainability Framework
March 27, 2023
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
March 16, 2023
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
February 28, 2023
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8: 00 am ET on March 2, 2023
February 26, 2023
Settlement of Alvotech Private Share Placement Completed
February 9, 2023
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)
February 5, 2023
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
January 23, 2023
Alvotech Completes $137 Million Private Share Placement
January 22, 2023
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
January 12, 2023
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
January 10, 2023
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
January 5, 2023